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ABSTRACT
Aim: To describe the early outcomes of carcinoid patients 
undergoing surgical heart valve replacement.
Methods: In a retrospective study, records of patients with 
symptomatic carcinoid heart disease referred for valve sur-
gery between 2012 and 2016 were reviewed. The periopera-
tive and early postoperative outcomes were analyzed.
Results: Nine patients, with a mean age of 61 years (range 
55-70 years) underwent cardiac surgery for carcinoid syn-
drome. 3 patients had quadruple valve replacement, 5 had 
tricuspid and pulmonary valves changed, while one had tri-
cuspid, pulmonary, and aortic valves replaced. Right-sided 
valves were replaced with biological valves in 8 patients 
and a mechanical valve in 1 patient. Left-sided valves were 
replaced with a mechanical valve in 2 patients and with a 
biological valve in 1 patient. Mean postoperative follow-up 
was 24 months (range 6-50 months, median 16 months). All 
patients had a good left ventricle except one, in whom it was 
mildly impaired. The right ventricle was severely dilated in 4 
patients, moderately in 2, and mildly in 3. One patient died 
of heart failure 10 days postoperatively. Functional improve-
ment was noted in all survivors, and they were in New York 
Heart Association class I at last follow up.
Conclusion: Although carcinoid syndrome is a rare 
and progressive disease, valve replacement in symptomatic 
patients is a reasonable option with survival benefit, low early 
postoperative mortality, without valve-related complications, 
and with functional improvement. Cardiac assessment is 
required in all patients with carcinoid disease from the earli-
est time of medical treatment to improve patients’ result.
INTRODUCTION
Carcinoid is a rare neuroendocrine tumour that occurs 
in 1.2 to 2.1 persons per 100,000 per year [Connolly 
2001a]. The appendix and the terminal ileum are the most 
common sites for the primary carcinoid tumor [Connolly 
2001b]. The tumor products released in the portal circu-
lation are inactivated by the liver. However, when liver 
metastases occur, these vasoactive substances can reach 
the right side of the heart without being inactivated by the 
first-pass metabolism in the liver, and carcinoid heart dis-
ease might evolve [Bernheim 2007; Raja 2010]. At diagno-
sis, 20% to 30% of patients have disseminated disease and 
consequent carcinoid syndrome [Castillo 2008a], which is 
characterized by facial flushing, diarrhea, and broncho-
spasm. Once carcinoid syndrome has developed, approxi-
mately 50% of these patients will go on to develop carci-
noid heart disease. The cardiac manifestations are caused 
by 5-hydroxytryptamine (5-HT or serotonin) released 
by the malignant cells rather than any direct metastatic 
involvement of the heart. 
Carcinoid heart disease distinctively involves tricuspid and 
pulmonary valves, and patients often present with right-sided 
heart failure. Mitral and aortic valve involvement is reported 
<10% of patients with carcinoid heart disease. Preferential 
right heart involvement is most likely related to inactivation 
of the vasoactive substances by the lungs. Thus, carcinoid dis-
ease of the left-sided heart valves may occur more frequently 
in patients with an atrial septal defect, patent foramen ovale 
(PFO), bronchopulmonary carcinoid, or high levels of circu-
lating serotonin [Gustafsson 2008].
Carcinoid heart disease is characterized histologically by 
diffuse collections of thick, pearly white plaque composed 
of smooth muscle cells called myofibroblast. [Ferrans 1976]. 
These plaques are deposited on the endocardial surface of the 
right atrium and on the endocardial surfaces of the valves on 
the right side of the heart, resulting in characteristic patho-
logic and echocardiographic features, which include thicken-
ing and immobility of the tricuspid valve and pulmonary valve 
leaflets [Roberts 1997; Pellikka 1993]. It results in combined 
stenosis and regurgitation.
Diagnosis is confirmed by elevation of the byproduct of 
serotonin metabolism, 5-hydroxy indole acetic acid (5-HIAA). 
The urinary 5-HIAA (24-hour collection) provides a reliable 
biological marker for the assessment of tumor activity and the 
response to therapy [Moertel 1987]. 
The purpose of this study was to present the early out-
comes of valve surgery in patients with carcinoid heart disease 
in our specialized center.
MATERIALS AND METHODS
Between December 2011 and June 2016, 9 patients under-
went valve replacement for carcinoid heart disease at our 
institution. 3 patients had quadruple valve replacement, 5 had 
tricuspid and pulmonary valves changed, while one had tri-
cuspid, pulmonary and aortic valves changed. All had been 
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diagnosed with a small bowel carcinoid tumor with liver 
metastases having initially presented with abdominal pain, 
flushing, and dyspnoea (NYHA 3-4). Computed tomography 
(CT) of the abdomen revealed multiple liver metastases and 
a small bowel mesenteric mass. A laparoscopic biopsy was 
consistent with a low-grade carcinoid tumor. All had good 
medium-term estimated prognoses but were deteriorating 
rapidly due to congestive heart failure. 
All patients had clinical signs and symptoms of right heart 
failure and echocardiographic evidence of carcinoid heart 
disease, including thickened valves with regurgitation. Three 
patients also had left-sided heart failure. Right sided valves 
had severe involvement with severe tricuspid and pulmonary 
valve regurgitation except in 1 patient, when it was moder-
ate. Examination of all patients revealed an elevated jugular 
venous pressure with prominent ‘V’ waves and bilateral pedal 
oedema. The coronary arteries were free from disease on 
angiography except in one patient.
Because of the severity of cardiac symptoms, given that 
their estimated life expectancy was more than two years and 
based on the course of their carcinoid disease, the patients 
were accepted for surgery. 
An intravenous infusion of Octreotide (600 µg in 60 mL 
0.9% saline) was commenced a day before surgery at a rate 
of 5 mL/h, delivering 50 µg/h Octreotide. This continued 
during surgery and stopped 48 hours after the operation. 
Surgery was performed with the patient on aorto-bicaval car-
diopulmonary bypass via a midline sternotomy. The patient’s 
systemic temperature was lowered to 32°C, with myocardial 
protection being achieved through antegrade cold blood car-
dioplegia, which was repeated every 30-45 minutes.
RESULTS
Patients’ preoperative, intraoperative, and postopera-
tive characteristics are shown in the Table. In patients with 
Preoperative, Intraoperative, and Postoperative Characteristics of Carcinoid Patients Operated for Valve Replacement
Patient 1 2 3 4 5 6 7 8 9
Age, y 56 55 55 62 65 62 62 62 70
Sex M F F F F M F M M
NYHA, preoperative 3 4 3 3 2 3 3 3 3
NYHA, postoperative 1 1 1 1 1 1 1 1 1
Surgery date Aug 2015 Nov 2015 Aug 2016 Dec 2012 Mar 2013 Apr 2014 Feb 2015 Jan 2016 Jun 2016
Follow up, mo 16 14 6 50 47 34 24 13 8
PFO No No No No No large No No No
X-clamp, min 177 197 164 0 0 82 104 91 85
Bypass, min 209 229 195 91 120 142 159 112 96
Aortic regurgitation M-S M-S S — — S — — —
Valve implanted 23 CM 23 PM 19 CM — — 25 PM — — —
Mitral regurgitation M-S S S — — — — — —
Valve implanted 27 CM 25 PM 27 CM — — — — — —
Tricus. regurgitation S S MIL S S S S S S
Valve implanted 29 PM 25 PM 25 PM 29 PM 29 CM 29 HP 25 PM 29 PM 33 PM
Pulm. regurgitation S S M-S S S S S S S
Valve implanted 23 PM 21 PM 23 PM 23 PM 27 CM 25 PM 23 PM 25 PM 27 PM
EUROscore 4 7 3 5 5 4 5 3 5
Logistic EUROscore 2.86 7.41 2.04 3.80 4.32 2.76 4.08 1.96 4.33
Left ventricle EF, % 50 40 55 55 50 55 55 55 45
Right ventricle Sev.d Pres. Mil.d Pres. Mil.d Pres. Mod.d Mod.im Sev.d Pres. Mil.d Mil.im Sev.d Mil.im Sev.d Sev.im Mod.d Pres.
ICU stay, d 2 2 3 4 1 2 9 1 2
Hospital stay, d 9 11 16 35 9 8 21 17 8
Chest drain, mL 2200 250 250 100 300 625 700 250 250
M indicates male; F, female; M-S, moderate to severe; S, severe; Mil, mild; CM, carbomedics valve; PM, perimount magna valve; HM, Hancock porcine biopros-
thesis; Mil.d, mildly dilated; Mod.d, moderately dilated; Sev.d: severely dilated; mil.im, mildly impaired; Mod.im, moderately impaired; Sev.im, severely impaired; 
Pres, preserved.
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quadruple valve replacement, right-sided valves had more 
severe involvement then left-sided valves. Intraoperative 
echocardiography identified a PFO with right-to-left shunt-
ing in 1 patient (43%) that was surgically confirmed and 
repaired. Notably, no defects were detected on preoperative 
transthoracic echocardiograms.
All patients had increased concentrations of urinary 
5-hydroxyindoleacetic acid; levels were similar in patients 
with or without a PFO.
Patients included 5 women and 4 men. Mean preoperative 
NYHA was 3 (range 2-4), while postoperative NYHA was 1 
in all patients. Mean age was 61 (range 55-70). Mean postop-
erative follow-up was 24 months (range 6-50 months, median 
16 months). Mean additive EUROscore was 4.55 (range 3-7) 
and mean logistic EUROscore was 3.72 (range 1.96-7.41). All 
patients had good left ventricle, except one patient in whom 
it was mildly impaired. Right ventricle was severely dilated 
in 4 patients, moderately in 2, and mildly in 3 patients. Right 
ventricle was preserved in 5 patients, mildly impaired in 2, 
moderately in 1, and severely in 1 patient. 
Right-sided valves were replaced with biological valves in 
8 patients and with a mechanical valve in 1 patient. Left-sided 
valves were replaced with mechanical valve in 2 patients and 
with a biological valve in 1 patient. The valves used were Car-
bomedics bileaflet mechanical heart valves and Carpentier-
Edwards Perimount Magna Ease Heart Valve. One patient 
had tricuspid and pulmonary valve replacement and coronary 
artery bypass grafting. Carcinoid disease patients often have 
impaired liver function with higher risk of bleeding, so we 
prefer to use tissue valve on the right side. Moreover, if need 
arises, it is easier to place permanent pacemaker leads in the 
presence of tissue valves.
Right ventricular outflow tract reconstruction (pulmonary 
augmentation) with a pericardial patch was performed in all 
patients. Patients were transferred to the intensive care unit 
in a hemodynamically stable condition, with a modest dose of 
adrenaline and noradrenaline. They were temporarily paced 
for four days with subsequent recovery of their intrinsic sinus 
rhythm at which point the pacing was discontinued. 
Mean ICU stay was 2.9 days (range 1-9 days, median 2 
days) while mean hospital stay was 15 days (range 8-35 days, 
median 11 days). Mean chest drain was 547 mL (range 100-
2200, median 250 mL). No patient experienced a carcinoid 
crisis. One patient was reopened for bleeding and there was 
one mortality (11%). All excised valves had clinical and patho-
logic findings consistent with carcinoid heart disease.
One patient died of heart failure 9 days postoperatively in 
ICU. She was a 63-year-old female. She had normal LV, severely 
dilated RA and RV, mildly impaired RV with gross TR, and pul-
monary stenosis. She underwent tricuspid and pulmonary valve 
replacement with tissue valve with single graft. Postoperatively 
her RV function became moderately to severely impaired. Her 
RV was unsuccessfully off-loaded with milrinone, nitric oxide, 
diuresis, and adrenaline. She also developed bilateral basal lung 
consolidation and died on day 10.
Functional improvement (eg, increased exercise tolerance, 
reduced lower extremity oedema, reduced ascites, resolu-
tion of orthopnoea, and paroxysmal nocturnal dyspnoea) was 
noted in all survivors. No thromboembolic events or bleeding 
complications occurred in our study population.
DISCUSSION
Bhattacharyya et al [Bhattacharyya  2011] noted that 
patients with carcinoid heart disease were referred for valve 
surgery if they had stable carcinoid tumor, severe valvu-
lar dysfunction, symptomatic, and had no other significant 
comorbidities.
The 5-year survival rate of patients without cardiac involve-
ment ranges from 70% to 80% for all carcinoid tumors [Zue-
tenhorst 2003]. Surgical valve replacement rather than repair 
needs to be considered because of the severe retraction and 
fixation of the leaflets [Castillo 2008b] and it is the only effec-
tive treatment for carcinoid heart disease [Connolly 2002]. 
It is suggested that tricuspid and pulmonary valve replace-
ment be considered when both valves are involved. It is true 
that many patients tolerate pulmonary regurgitation, but it 
is observed that patients who have a competent pulmonary 
valve have a much smoother postoperative recovery than do 
patients who have tricuspid valve replacement and pulmonary 
valvectomy. It appears that long-standing severe pulmonary 
valve regurgitation, as seen after pulmonary valvectomy, may 
have a detrimental effect on right ventricular remodelling 
[Connolly 2002]. In the pulmonary position, a stentless bio-
prosthesis is preferred because of its excellent hemodynamic 
characteristics and flexibility [Takahashi 2009].
There is some debate regarding selection of the pros-
theses in carcinoid patients. Mechanical prostheses are not 
ideal because patients with carcinoid syndrome often have 
extensive liver metastases and hepatic dysfunction, and they 
are at high risk of bleeding due to the use of lifelong anti-
coagulation. Early reports recommended using a mechanical 
prosthesis based on the assumption that circulating vasoactive 
tumor substances may damage bioprosthetic valves. Indeed, 
premature bioprosthetic degeneration has been reported in 
carcinoid patients [Ridker 1991].
Bioprosthetic valves can be potentially protected from the 
damaging effects of vasoactive substances by octreotide and 
hepatic artery interruption. There is less risk of involvement 
of bioprosthesis in the carcinoid process, once the primary 
carcinoid tumor is surgically removed [McDonald 1999]. 
The Mayo Clinic experience [Arghani 2010] suggested 
that cardiac valve replacement for symptomatic patients had 
a beneficial effect, causing a reduction in right ventricular 
size during the postoperative period. Komoda et al [Komoda 
2011] suggested that the predictors of postoperative outcome 
may be not only signs of right ventricular failure, such as 
right ventricular volume overload and right ventricular func-
tion, but also preoperative left ventricular function in these 
patients. They also stressed the timing of cardiac surgery in 
patients with carcinoid heart disease. Presently, it is consid-
ered preferable for patients with stable carcinoid tumor to 
undergo surgery early after the onset of cardiac symptoms, 
as delay can result in worsening right ventricular failure and 
increase the risk of surgery. Hence, echocardiography is cru-
cial in patients with carcinoid disease.
Carcinoid Heart Disease: Early Outcomes after Surgical Valve Replacement in Nine Patients—Mujtaba et al
E43© 2018 Forum Multimedia Publishing, LLC
Although most of our patients were severely ill, in NYHA 
class 3-4 and with symptoms of right heart failure, our results 
show an 89% early postoperative survival. In this study, we 
show significant improvement in functional capacity after 
valve replacement for carcinoid heart disease, without valve-
related complications and low perioperative mortality. 
Conclusion
Carcinoid heart disease is an uncommon and complex form 
of valvular heart disease. Cardiac involvement is a major cause 
of morbidity and mortality. Despite metastatic disease that 
limits longevity, valve replacement in symptomatic patients 
is a reasonable option with survival benefit, low early-post-
operative mortality, without valve-related complications and 
with functional improvement. Cardiac assessment is required 
in all patients with carcinoid disease from the earliest time of 
medical treatment to improve patients’ results.
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